Informations générales (source: ClinicalTrials.gov)
Genomic and Proteomic Study of Richter Syndrome (CGPSR)
Observational
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
septembre 2017
septembre 2024
08 mars 2025
Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic
Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive
Diffuse Large B-Cell Lymphoma (DLBCL), but is associated with a poor prognosis, due to
chemorefractoriness.
This study aims at understanding the biological determinants of chemotherapy resistance
in Richter Syndrome.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHRU de Nancy - 54035 - Nancy - France | Véronique SAUNIER | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Diagnosis of a Diffuse Large B-Cell Lymphoma arising in the context of a Chronic
Lymphocytic Leukemia (group 1) or diagnosis of a primitive Diffuse Large B-Cell
Lymphoma (group 2), or diagnosis of a Diffuse Large B-Cell Lymphoma arising in a
context of small cells lymphoma, excluding CLL (group 3), or benefit from a
diagnostic lymph node biopsy that did not reveal any tumor involvment (primitive or
metastatic) (group 4).
- Patients must benefit from a lymph node biopsy at diagnosis.
- Patients must be followed by a FILO (French Innovative Leukemia Organization) member
- Histology of Diffuse Large B-Cell Lymphoma or Hodgkin histology.
- Suitable clinical data available.
- Samples must meet the following requirement :RIN (RNA Integrity Number) > 5 et DIN
(DNA Integrity Number) > 6.5.
- Diagnosis of a Diffuse Large B-Cell Lymphoma arising in the context of a Chronic
Lymphocytic Leukemia (group 1) or diagnosis of a primitive Diffuse Large B-Cell
Lymphoma (group 2), or diagnosis of a Diffuse Large B-Cell Lymphoma arising in a
context of small cells lymphoma, excluding CLL (group 3), or benefit from a
diagnostic lymph node biopsy that did not reveal any tumor involvment (primitive or
metastatic) (group 4).
- Patients must benefit from a lymph node biopsy at diagnosis.
- Patients must be followed by a FILO (French Innovative Leukemia Organization) member
- Histology of Diffuse Large B-Cell Lymphoma or Hodgkin histology.
- Suitable clinical data available.
- Samples must meet the following requirement :RIN (RNA Integrity Number) > 5 et DIN
(DNA Integrity Number) > 6.5.
• Samples that do not meet the inclusion criteria (insufficient clinical data, analysis
impossible due to insufficient sample quality).